The Political Economy of Infrastructure in the UK

whitePaper | March 24, 2023

Workday Government Cloud offers U.S. federal agencies a world-class portfolio of financial management and human capital management cloud applications running in an environment with a FedRAMP Moderate authorization. Workday Government Cloud enables organizations to effectively and securely manage their demanding workforce, finance, and mission processes while helping to meet new Zero Trust Architecture (ZTA) strategy mandates

whitePaper | January 22, 2020

Trade in “services” refers to a wide and growing range of economic activities. These activities include transport, tourism, financial services, use of intellectual property, telecommunications and information services, government services, maintenance, and other professional services from accounting to legal services. Compared to goods, the types and volume of services that can be traded are limited by factors such as the requirement for direct buyer-provider contact, and other unique characteristics such as the reusability of services (e.g., professional consulting) for which traditional value measures do not account. In addition to services as independent exports, manufactured and agricultural products incorporate and depend on services, such as research and development or shipping of intermediate or final goods. As services account for 71% of U.S. employment, U.S. trade in services, both services as exports and as inputs to other exported products, can have a broad impact across the U.S. economy.

whitePaper | August 8, 2022

Over the last almost two years, the COVID-19 pandemic has catalysed the UK government’s digital transformation. Remarkable transition to remote working, rapid delivery of new digital services, and scaling of existing IT systems to meet increased demand have demonstrated the power of digital and paved the way for building a digitally led public sector. Additionally, predominant digital inefficiencies have become clearer, whilst new citizen and staff expectations have been set. But how do government departments plan to build on and sustain this recent impetus to digital transformation in the coming years?

whitePaper | March 3, 2020

Artificial intelligence (AI) systems have raised concerns in the public—some speculative and some based in contemporary experience. Some of these concerns overlap with concerns about privacy of data, some relate to the effectiveness of AI systems and some relate to the possibility of the misapplication of the technology. At the same time, the development of AI technology is seen as a matter of national priority, and fears of losing the “AI technology race” fuel national efforts to support its development.

whitePaper | August 11, 2022

Organizations in the public sector are moving from a single-cloud community to a multicloud one. Examples of this have already been seen in the intelligence community and Department of Defense space with the introduction of the Commercial Cloud Enterprise (C2E) and Joint Warfighter Cloud Capability (JWCC) contracts. These are just two examples of the massive shift that is occurring across the entire public sector as it modernizes to integrate multiple cloud providers. Leadership needs to plan for the impact this will have on the way programs are staffed and the way systems are engineered and tested. Successful multi-cloud adoption requires thoughtful, purposeful action. A broader availability of cloud service providers (CSPs) means that federal organizations must become smarter and more discerning cloud customers

whitePaper | December 10, 2019

The Trump administration, members of Congress from both parties, and many states have introduced proposals to combat high drug prices. Too often missing from these reform efforts, however, is a clear understanding of a root cause of the crisis: the suppression of fair market competition through various forms of monopoly. This white paper examines and proposes solutions for the two main ways that monopoly drives up the costs and lowers the quality of prescription drugs: increasing corporate concentration in the pharmaceutical industry, and the monopoly markets for individual drugs created by a deeply flawed and increasingly abused patent and regulatory system.